MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: recurrence-free survival
MedXY News
EnglishTag

recurrence-free survival

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Adjunctive Metformin with Progestin in Fertility-Sparing Treatment of Endometrial Neoplasia: Insights from the FELICIA Trial
newsmetforminrecurrence-free survival

Adjunctive Metformin with Progestin in Fertility-Sparing Treatment of Endometrial Neoplasia: Insights from the FELICIA Trial

By MedXY|Oct 20, 2026

The FELICIA phase IIb trial found that adding metformin to progestin therapy for fertility-sparing treatment in endometrial neoplasia did not improve 3-year recurrence-free survival or remission rates, though some reproductive outcomes favo

Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update
Dermatology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
melanoma
Daromun

Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update

By MedXY|Aug 13, 2026

Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration
newsCT 影像high-grade serous ovarian cancer

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration

By MedXY|Jul 5, 2026

This study demonstrates that combining clinical variables with computed tomography radiomics features improves the prediction of recurrence-free survival in high-grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy and s

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety
Dermatologyimmunotherapymelanoma

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

By MedXY|Oct 25, 2025

The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models